While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Tricia Rodriguez, Truveta senior applied research scientist & lead study author, explains the study findings concerning why ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

The paper used data from Numerator, which surveyed 150,000 households about GLP-1 medications and food purchasing ... On the other hand, the study noted that nutrient-dense options such as yogurt ...

Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and ...

"The purpose of our clinical study series is to assess isomyosamine’s potential to preserve lean muscle mass during and following GLP-1 weight loss in chronic overweight and obese patients of ...

GLP-1 agonists can address obesity ... As the company continues its third and fourth human study in the class and prepares to launch its fifth, management is reaching out to potential partners ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

"The study's results provide insights into some ... guiding prospective studies to explore potential benefits or risks. GLP-1-directed drugs have already shown promise in clinical trials involving ...